MedPharm's Services Flyer

PDF 796 kB

MedPharm is the world’s leading contract provider of topical and transdermal product design and development services. Our delivery of robust and innovative research has commanded recognition from regulators and investors alike. We utilise our unique cost-effective performance testing models to mitigate risk and accelerate development times. Find out more about MedPharm and how our development services can support you and your product's development in our flyer.

Content provided by our supplier

MedPharm, Ltd

GB
2018

On CPHI since
100 - 249

Employees

Company types

Contract Service

Other Content from MedPharm, Ltd (9)

News MedPharm expands topical and transdermal delivery services

A new location in Raleigh-Durham, North Carolina, close to the CDMO's Center of Excellence, will double its current footprint

2 Jun 2021
News Positive update on the development of new XF‐platform drug formulations

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

24 Mar 2020
News FDA success for MedPharm Centre of Excellence

The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.

14 Feb 2020
News MedPharm moves into $4M expansion of its North Carolina facility

Expansion increases capacity for the company's topical and transdermal services, as well as dedicated innovation, microbiology and histology laboratories.

5 Dec 2019
News MedPharm expands relationship with Novan on formulation science

New agreement allows MedPharm to react quickly to changes in requirements and makes full use of its comprehensive services for de-risking Novan’s product development.

23 Jul 2019
News MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

Provides a guide on all aspects of the subject with much of the information based on the systems, processes and expertise built up at MedPharm.

28 Apr 2019
News MedPharm's appointment with Destiny

Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.

28 Mar 2019
News Partnership expands to develop a new treatment for pachyonychia congenita

MedPharm and Palvella Therapeutics hope to develop the first approved treatment for PC in the US and Europe.

19 Feb 2019
News MedPharm expands to de-risk customers' development programs

The $4-million investment will be used to expand topical dosage formulation development services and innovative performance testing on topical and transdermal pharmaceutical products.

14 Jan 2019